Drugs / VUM02 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06230822 | Feb 2024 → Jan 2025 overdue | idiopathic pulmonary fibrosis | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VUM02 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06230822 ↗ |
| Modality | Cell therapy | “is an allogeneic cell therapy product” NCT06230822 ↗ |
| Route | Intravenous | “VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.” NCT06230822 ↗ |